Our analysis reflected that most studies address these critical aspects of cardiovascular health, discussing the potential role of DPP-4 inhibitors in mitigating adverse outcomes, particularly in patients with T2DM. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.